#Transdermal delivery system

[curiousquill1]

https://www.vjinstruments.com/products/rapid-mixer-granulator/

The Rapid Mixer Granulator by VJ Instruments is a game-changer for pharmaceutical manufacturing, seamlessly combining mixing and granulation processes to enhance efficiency and reduce production time. It ensures uniform particle size distribution crucial for product quality, while its user-friendly design and intuitive interface allow for real-time adjustments. Utilizing high shear mixing technology, it achieves thorough blending for improved dissolution and bioavailability of active pharmaceutical ingredients. Versatile enough for various formulations, the machine facilitates easy cleaning, ensuring compliance with hygiene standards, and features robust construction for durability. With enhanced production scalability and energy efficiency, it stands as a vital investment for manufacturers looking to optimize their operations and product quality.

[businesspointnews]

Transdermal Drug Delivery Systems Market Size, Share, Demand, Growth Drivers , Key Players and Forecast 2023-2028

IMARC Group has recently released a new research study titled “Transdermal Drug Delivery Systems Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.How big is the transdermal drug…

[desaletushki]

Transdermal Drug Delivery System Market Revenue Forecast 2030

Transdermal Drug Delivery System Market Growth & Trends

The global transdermal drug delivery system market is expected to reach USD 145.0 billion by 2030, registering a CAGR of 11.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing adoption of transdermal patches, such as in the case of diabetes, which requires sustained and a daily dose of insulin is expected to provide the market with growth opportunities during the forecast period.

High demand for pain-free drug delivery is a major driving factor of the transdermal drug delivery systems market. In the case of diabetes, insulin has to be administered into the patient's body with the help of injections on a continuous basis. Continuous usage of injections to deliver insulin causes pain and increases the risk of transmission of chronic diseases, thus, making transdermal patches a better choice for delivering insulin in diabetic patients.

Request a free sample copy or view the report summary: https://www.grandviewresearch.com/industry-analysis/transdermal-drug-delivery-systems-industry

COVID-19 led to a significant fall in sales of transdermal drug delivery systems. This is because most of these drugs are prescribed drugs and the pandemic led to a sharp fall in patient visits to healthcare facilities. Factors such as lockdowns and travel restrictions led down by the government, to curb the spread of the virus, resulted in reduced patient visits. In addition, many individuals in order to avoid physical contact also avoided visiting healthcare facilities, as a precautionary measure.

However, with the world moving towards normalcy and various pharma companies focusing on developing new novel products, the market represents great opportunities for growth. Moreover, increasing investments by the government in R&D and healthcare are further accelerating the demand for transdermal drug delivery systems in the market.

Transdermal Drug Delivery System Market Report Highlights

The iontophoresis segment dominated the market in 2022 owing to its efficacy in delivering drugs. The mechanical arrays segment is expected to maximum growth due to the increasing number of product launches

The pain management segment accounted for the highest market share in 2022 due to increasing demand for transdermal patches used for pain management

The cardiovascular segment is anticipated to experience maximum growth during the forecast period due to the increasing utilization of these systems in the treatment of cardiovascular diseases

North America accounted for the highest market share in 2022 owing to a rise in investments by existing as well as new market players

Increasing healthcare expenditure and huge investments in research and development represent lucrative growth opportunities in the Asia Pacific region

Transdermal Drug Delivery System Market Segmentation

Grand View Research has segmented the global transdermal drug delivery system market based on technology, application, and region:

Transdermal Drug Delivery System Technology Outlook (Revenue in USD Million, 2018 - 2030)

Electroporation

Radio Frequency

Iontophoresis

Microporation

Thermal

Mechanical arrays

Ultrasound

Others

Transdermal Drug Delivery System Application Outlook (Revenue in USD Million, 2018 - 2030)

CNS

Pain Management

Cardiovascular

Hormone

Immunological

Metabolic

Gastrointestinal

Infection

Cancer

Others

Urological

Blood disorders

Respiratory

Musculoskeletal

Regional Insights

North America held a sizeable share of more than 58.2% in 2022. The growth in this region is majorly driven by patent expirations, resulting in more companies entering the market. In addition, repositioning of previously failed drugs, reformulation of existing drug compounds, and huge investments undertaken by the prominent as well as new market entrants are also presumed to be the key factors responsible for the substantial share captured by this region.

Factors such as favorable reimbursement scenarios and rising awareness by government organizations in Europe are contributing to the growth of the transdermal drug delivery system market in the region. Well-developed healthcare structure that covers the healthcare costs of the citizens, promotes more people opting for treatment in the region. This is expected to further boost the market growth during the forecast period.

The Asia Pacific market is anticipated to exhibit the fastest CAGR of above 13.4% during the forecast period, attributable to the growing healthcare spending and the rapidly evolving healthcare infrastructure. In addition, the growth is due to the high research and development intensity as well as the growing awareness in emerging economies, such as China and India.

List of Key Players in Transdermal Drug Delivery System Market

Novartis AG

Johnson & Johnson

Mylan Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Biogel Technology, Inc.

Transdermal Technologies, Inc.

Skyepharma, Watson Pharmaceuticals, Inc.

3M Company

Noven Pharmaceuticals, Inc.

4P Therapeutics, LLC

Transdermal Corporation

Echo Therapeutics, Inc.

Authoritative Research: https://www.grandviewresearch.com/industry-analysis/transdermal-drug-delivery-systems-industry

[qy-research-medical]

The U.S. transdermal drug delivery system market size was valued at USD 31.31 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 12.4% from 2023 to 2032.

[poojaj]

Excellent growth of Transdermal Drug Delivery System Market

The transdermal drug delivery system market refers to the global market for drug delivery systems that use the skin as a route of administration. Transdermal drug delivery systems are used to deliver drugs through the skin and into the bloodstream, and are used in the treatment of a wide range of conditions, including pain management, hormone replacement therapy, nicotine addiction, and cardiovascular disease.

For Sample Report Click Here:-https://www.globmarketreports.com/request-sample/202344

The global transdermal drug delivery system market is expected to experience significant growth in the coming years, driven by factors such as the increasing prevalence of chronic diseases, the growing demand for non-invasive drug delivery systems, and the increasing adoption of transdermal drug delivery systems by pharmaceutical companies.

North America is expected to be the largest market for transdermal drug delivery systems, due to the high prevalence of chronic diseases, the presence of a well-established healthcare infrastructure, and the increasing adoption of advanced transdermal drug delivery systems. The Asia-Pacific region is also expected to experience significant growth in the coming years, driven by factors such as the increasing demand for non-invasive drug delivery systems and the growing focus of pharmaceutical companies on developing innovative transdermal drug delivery systems.

A transdermal drug delivery system (TDDS) is a medical technology that enables the transfer of drugs or other therapeutic agents through the skin and into the bloodstream. The system consists of a patch that is applied to the skin, which contains the drug in a specific formulation that allows it to penetrate the skin layers and reach the bloodstream.

TDDS has several advantages over traditional drug delivery methods, such as oral or injectable administration. It can provide a controlled and continuous release of the drug over a prolonged period of time, ensuring consistent blood levels of the drug. It also avoids the first-pass metabolism of the liver, which can reduce the effectiveness of the drug and cause unwanted side effects.

[jgbgff]

Transdermal Drug Delivery System Market Size, Share & Trends, Product, Region & Forecasts 2030

Transdermal Drug Delivery System Market Size, Share & Trends, Product, Region & Forecasts 2030

Description The impact of a number of factors such as economic, legal, social, political, technological, and modern business developments on market dynamics is briefly examined in the Transdermal Drug Delivery System market analysis. The global Transdermal Drug Delivery System market analysis focuses on market share and competitiveness index, which helps evaluate the top player’s contributions to…

[unwelcome-ozian]

What information do you have about Johnson & Johnson?

Alza filed an NDA for the transdermal opioid analgesic product in December 1987 for post-operative use and for the relief of chronic cancer pain. Developed by J&J subsidiary Janssen Pharmaceutica, fentanyl has been marketed since 1968 under the Sublimaze brand. The drug is currently approved for I.V. administration and used primarily as a short-acting analgesic during anaesthesia. "This new drug delivery system will make it possible for the first time to use fentanyl . . . outside the operating room to control moderate to severe pain." Source

US opioids: Johnson and Johnson and drug distributors offer $26bn to end thousands of lawsuits. Source

The drug company Johnson & Johnson (J&J) has expressed regret after court documents unsealed in talcum powder litigation showed that it funded a 1971 study in which Pennsylvania prison inmates, most of them black, were injected subcutaneously with asbestos. Source

Asbestos Prisoner Study May Spell More Problems for Johnson & Johnson

WASHINGTON - Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider.  The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 billion. Source

Johnson & Johnson paused all clinical trials of its experimental COVID-19 vaccine after a study participant became sick with an "unexplained illness."

Johnson & Johnson has suspended international trials of a drug in the same class as an experimental drug made by Portuguese pharmaceutical company Bial, whose tests in France left one person brain dead and five others hospitalised. Source

1982 - McNeil

Product Recalled - Tylenol (acetaminophen) capsules

Reason for Recall - Medicine laced with potassium cyanide (poison) resulting in several patient deaths.

2009 to 2011 - McNeil

Product Recalled - Several OTC medicines including Tylenol, Motrin, Benadryl, St. Joseph aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec, Zyrtec Eye Drops (tens of millions of bottles)

Reason for Recall - Unpleasant smells causing nausea; tiny metal shards in liquid medicines; wrong ingredient levels

2010 - DePuy [Pinnacle Systems]

Product Recalled - ASR Hip Resurfacing System and ASR XL Acetabular System (metal-on-metal hip implants)

Reason for Recall - Metal poisoning (metallosis); loosening of the implant or joint dislocation; additional surgeries

2012 - Ethicon

Product Recalled - Gynecare Prolift Kit, Gynecare Prolift+M Kit, Gynecare TVT Secure and Gynecare Prosima Pelvic Floor Repair System Kit (transvaginal mesh implants)

Reason for Recall - Perforation of organs; vaginal bleeding and scarring; mesh erosion; severe pain

2014 - Ethicon

Product Recalled - Power Morcellators

Reason for Recall - Spread of uterine cancer; rapid progression of the disease; death

2019 – Johnson & Johnson

Product Recalled – 33,000 bottles of Johnson’s Baby Powder

Reason for Recall – The FDA found a small amount of asbestos — a known carcinogen — in a sample

Xarelto

Number of Lawsuits - 13,511

Injuries - severe, sometimes deadly bleeding events, blood clots, wound leaks, infection

J&J was involved in seven of 2017’s top ten health-care-related verdicts.

The company was also involved in the third-largest pharmaceutical settlement with the U.S. Department of Justice. In 2013, J&J paid the Justice Department more than $2.2 billion. The settlement resolved civil and criminal allegations involving Risperdal, Invega and Natrecor.

May 2017

J&J paid $33 million to most U.S. states and the District of Columbia. The states charged J&J with misrepresenting the manufacturing practices behind certain drugs. This included its Motrin products. These products were later recalled.

Oz

[credenceresearchdotblog]

The global topical drug delivery market is projected to grow from USD 124,905.5 million in 2024 to USD 245,252.09 million by 2032, reflecting a compound annual growth rate (CAGR) of 8.80%.The topical drug delivery market is a vital segment of the pharmaceutical industry, focusing on the administration of medications directly to the skin or mucosal surfaces for localized or systemic effects. This method is widely utilized for treating a range of conditions, including dermatological, ocular, and musculoskeletal disorders. With advancements in technology and increasing consumer demand for non-invasive treatment methods, the market has been experiencing significant growth. This article explores the dynamics, drivers, and future trends shaping the topical drug delivery market.

Browse the full report at https://www.credenceresearch.com/report/topical-drug-delivery-market

Market Overview

Topical drug delivery involves the application of drugs through gels, creams, ointments, sprays, or patches. This route is particularly favored for its ability to provide localized treatment, minimize systemic side effects, and improve patient compliance. Over the years, the market has expanded significantly due to the rising prevalence of chronic skin diseases, technological advancements in drug formulations, and the growing preference for non-invasive drug delivery systems.

In 2023, the global topical drug delivery market was estimated to be valued at over $100 billion and is expected to grow at a compound annual growth rate (CAGR) of approximately 7% during the forecast period of 2023–2030.

Key Drivers of Market Growth

Prevalence of Skin Disorders The increasing incidence of skin conditions such as psoriasis, eczema, acne, and dermatitis is a significant factor driving the market. The World Health Organization (WHO) reports that over 900 million people globally suffer from skin diseases, boosting the demand for topical treatments.

Growing Geriatric Population Aging populations in regions such as North America, Europe, and parts of Asia have led to a surge in age-related conditions like arthritis and neuropathic pain, further increasing the demand for topical analgesics and anti-inflammatory products.

Advancements in Drug Delivery Technologies Innovations such as nanotechnology-based formulations, liposomes, and transdermal patches have improved drug absorption, efficacy, and patient experience, thereby driving market growth. Products like medicated patches for hormone replacement or pain management exemplify this trend.

Rising Consumer Preference for Non-Invasive Options Consumers increasingly seek alternatives to oral or injectable medications due to their associated side effects or discomfort. Topical drug delivery meets this demand, offering a painless and convenient solution.

Challenges Facing the Market

While the topical drug delivery market holds immense potential, it is not without challenges.

Skin Irritation and Allergic Reactions Some patients may experience adverse reactions to topical drugs, which can limit their use and effectiveness.

Complex Manufacturing Processes Advanced formulations such as nanotechnology-based drugs require sophisticated production techniques, driving up costs and potentially delaying market entry.

Regulatory Hurdles The stringent approval processes for topical drugs, especially those claiming systemic effects, can slow innovation and commercialization.

Future Trends and Opportunities

Expansion into Emerging Markets Rapid urbanization, increasing healthcare awareness, and improving economic conditions in countries like India, China, and Brazil present vast growth opportunities for the topical drug delivery market.

Personalized Medicine The integration of genetic and biomarker data with drug development could lead to personalized topical treatments, enhancing their effectiveness and reducing side effects.

Eco-Friendly Packaging With rising environmental concerns, companies are focusing on sustainable packaging solutions, such as biodegradable tubes and recyclable materials, to align with consumer preferences.

Combination Therapies The use of topical drugs in combination with other therapies, such as phototherapy or oral medications, is gaining traction, particularly in dermatology and oncology.

Key Player Analysis:

Galderma S.A.

GlaxoSmithKline plc

Bayer AG

Novartis AG

Valeant Pharmaceuticals International, Inc.

Cipla Ltd.

MedPharm Group Ltd.

Johnson & Johnson

3M Company

Crescita Therapeutics Inc.

Segmentations:

By Formulation:

Liquid Formulations

Semi-Solid Formulations

Solid Formulations

Transdermal Patches

By Route of Administration:

Dermal

Rectal

Vaginal

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/topical-drug-delivery-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

[curiousquill1]

How VJ Instruments' Transdermal Patch Machine is Changing the Future of Drug Delivery

The pharmaceutical industry has found a shift in drug delivery mechanisms. Changes are opening the doors to a true future in the drugs that manufacturers produce, and it all starts with the innovative action of the new Transdermal Patch Machine made by VJ Instruments. It has revolutionized how drugs are administered, absorbed, and consumed by patients around the world.

Opening the New Frontier of Drug Delivery

Transdermal patches are another alternative route to oral medications and injections, going directly to the bloodstream, thus providing controlled delivery of drugs without the natural digestive system. However, among the major barriers of its general use, this particular manufacturing process had been the initial obstacle—until VJ Instruments' Transdermal Patch Machine.

The use of the most recent breakthroughs in material science and advanced engineering guarantees that each piece is crafted with precision and uniformity. Innovative polymer technologies and drug encapsulation techniques maximize drug delivery, minimize side effects, and improve therapy.

Healthcare Benefit

The impact of this technology doesn't end at the manufacturing stage:

Increased convenience is now available to patients suffering from pill fatigue.

Tailored dosing regimens reveal new hope in the treatment of chronic diseases.

This innovation leads to higher patient compliance along with better outcomes.

A Closer Look at the Machine's Innovative Features

What makes VJ Instruments' Transdermal Patch Machine stand out? Let's look closer:

Nano-Precision Drug Layering

The proprietary nanotech used in the machine for creating ultrathin multi-layered patches controls drug release to give patients what they need, exactly when they want it.

Smart Polymer Integration

Incorporates self-healing polymers that respond to environmental conditions, such as temperature and pH. These polymers will eventually be able to deliver drugs directly at the site in real-time and based on patient needs.

Rapid Prototyping

3D printing modules are included to provide pharmaceutical companies with the opportunity to try rapid patch designs immediately. This will significantly shorten the time it takes from concept to market-ready product.

Machine Learning Quality Control

Advanced algorithms scan every production process. There is an assurance of high-quality patches, along with a reduction of unnecessary waste and costs involved in producing products.

Scalable Manufacturing

From clinical trials to full-scale manufacturing, the machine's modular design allows easy scaling while maintaining quality and efficiency.

These features benefit manufacturers and patients in real life. Pharmaceutical companies can now develop transdermal patches for a wider range of drugs, opening up new treatment possibilities and developing profitable product lines.

Impact on Patient Care and Market Dynamics

VJ Instruments' Transdermal Patch Machine is quite revolutionary, bringing about some major changes in the healthcare sector.

Enhanced Compliance: Patches as drug delivery systems reduce the dropout rate of treatments among patients suffering from chronic diseases, including hypertension and diabetes.

Reduced Adverse Reactions: Through its controlled release mechanism, the technology reduces the adverse effects that would have been manifested due to the fluctuating concentration levels of the drugs, thus improving the quality of life for patients.

Specialized Care for Fragile Patients: It delivers the exact dose to pediatric and geriatric patients; hence, it becomes a safe and easy alternative to oral drugs for such patients.

Market Size: As the machine can produce advanced transdermal patches, it opens doors in a global market that can reach billions of dollars.

Cost Savings: Although the investment is high, its efficiency, low waste, and combination of therapies within a single patch yield massive downstream value for any pharmaceutical company.

The Future is Now: Why VJ Instruments' Machine is a Must-Have

When it comes to keeping pace with the advancing pharmaceutical industries, VJ Instruments' Transdermal Patch Machine is a must-have tool for pharmaceutical companies. Why?

First-Mover Advantage

Early adopters can capture significant market share because the demand for the latest transdermal therapies is rapidly building up.

Regulatory Advantage

High-precision and quality control guarantee a hassle-free process towards obtaining new transdermal products regulated on the market.

Accelerated R&D Cycles

Rapid prototyping of novel therapy is made possible by the machine, leading to faster time-to-market for the company's therapy portfolio.

Sustainability

Energy and material efficiency in the design of the equipment resonate with the growing demand for sustainability in the pharma business.

Such innovative drug delivery solutions distinguish pharmaceutical companies in a booming market.

The Age of Revolution for Drug Delivery IS HERE

Away from pills and toward transdermal patches—the future is here, with VJ Instruments at the forefront of it. Having innovation, efficiency, and precision in one device, their Transdermal Patch Machine ensures patients are put first by pharmaceutical manufacturers and gives manufacturers that much-needed competitive edge.

Want to be part of the revolution?

[chicksbefore-dadicks-blog-blog]

Check out this listing I just added to my Poshmark closet: Kat Burki Micro Skin Firming Wand.

[aishavass]

North America accounted for the largest share of the global transdermal drug delivery system market in 2020 and is expected to retain its position through...